The Pfizer-BioNTech (COMIRNATY) vaccine was 95 percent effective in preventing laboratory-confirmed infection with the virus that causes COVID-19 in persons who received two doses and had no signs of being previously infected, according to results from clinical studies in people ages 16 and older.

The Pfizer-BioNTech vaccine exhibited >90% efficacy in clinical trials in preventing laboratory-confirmed COVID-19 infection in children aged 5–15 years, and the immune response in children aged 5–15 years was at least as robust as the immune response in persons aged 16–25 years.

In clinical trials, the vaccine also had >90% efficacy in preventing COVID-19 among patients of all ages, genders, races, and ethnicities, as well as those with underlying medical disorders.

MORE INFORMATION:
Manufacturer: Pfizer, Inc., and BioNTech
Number of Shots: 2 shots, 21 days apart
Moderately or severely immunocompromised people ages 5 years and older should get an additional primary shot at least 28 days after their second shot.
Type of Vaccine: mRNA

According to clinical trial evidence, the Moderna COVID-19 vaccine was 94.1 percent effective in preventing laboratory-confirmed COVID-19 infection in people ages 18 and older who received two doses and had no evidence of being previously infected in people who received two doses and had no evidence of being previously infected.

In clinical studies, the vaccination was also successful at preventing COVID-19 across patients of all ages, genders, races, and ethnicities, as well as those with underlying medical disorders.

Evidence suggests that mRNA COVID-19 vaccinations provide similar protection in real-world settings as they do in clinical trials, lowering the risk of COVID-19, including severe illness, by 90 percent or more among those who are fully vaccinated.

MORE INFORMATION:
Manufacturer: ModernaTX, Inc.
Number of Shots: 2 shots, 28 days apart
Moderately or severely immunocompromised people should get an additional primary shot (third dose) at least 28 days after their second shot.
Type of Vaccine: mRNA

The COVID-19 Vaccine AstraZeneca (AZD1222; sold as Vaxzevria in Europe) had a 76 percent efficacy against symptomatic SARS-CoV-2 infection. However, this is only applicable to occurrences occurring 15 days after the second dose, with a 29-day inter-dose gap.

Data reveal that two doses of the AstraZeneca vaccine were effective against symptomatic sickness caused by the Delta variant (74.5 percent, CI 68–89 percent) in comparison to the Alpha variant (74.5 percent, CI 68–89 percent). The UK Health Security Agency discovered that Delta had a 71 percent (CI 51–83 percent) effectiveness against hospitalization after one dosage and a 92 percent (CI 75–97 percent) effectiveness after the second dose.

Overall, research demonstrates that the AstraZeneca vaccine is highly effective against the Delta form, particularly in terms of hospitalization.

MORE INFORMATION:
Manufacturer: AstraZeneca Plc.
Number of Shots: 2 shots, 4 to 12 weeks apart
Type of Vaccine: Viral Vector

A large phase 3 trial in Brazil found that two doses of CoronaVac, administered 14 days apart, had a 51 percent efficacy against symptomatic SARS-CoV-2 infection, a 100 percent efficacy against severe COVID-19, and a 100 percent efficacy against hospitalization beginning 14 days following the second dose.

In an observational trial, the estimated efficiency of Sinovac-CoronaVac against symptomatic infection in health professionals in Manaus, Brazil, where P.1 accounted for 75% of SARS-CoV-2 samples was 49.6 percent. In the presence of P1 circulation, effectiveness was also demonstrated in observational research conducted in Sao Paulo (83 percent of samples).

Assessments in areas where the P.2 Variant of Concern was widely circulating indicated vaccination efficacy at 49.6 percent after at least one dose and 50.7 percent two weeks later.

MORE INFORMATION:
Manufacturer: Sinovac Biotech Ltd.
Number of Shots: 2 shots, 14 to 28 days apart
Type of Vaccine: Inactivated

In clinical studies, the J&J/Janssen COVID-19 vaccine was 66.3 percent effective at preventing laboratory-confirmed COVID-19 infection in people who received the vaccine and had no evidence of prior infection (efficacy). The best protection was obtained two weeks following vaccination.

In clinical trials, the vaccination was found to have a high efficacy in averting hospitalization and mortality in patients who did become ill.

MORE INFORMATION:

Manufacturer: Janssen Pharmaceuticals Companies of Johnson & Johnson

Number of Shots: 1 shot may be given in some situations.

Type of Vaccine: Viral Vector

A large multi-country Phase 3 trial found that two doses of BBIBP-CorV (Sinopharm BIBP COVID-19 vaccine) given at 21-day intervals had a 79 percent efficacy against symptomatic SARS-CoV-2 infection 14 or more days following the second dose. The vaccine has a 79 percent efficacy against hospitalization.

The trial was not planned or powered to establish efficacy against severe disease in people with comorbidities, during pregnancy, or in people over the age of 60. In the trial, women were underrepresented. At the time of the evidence review, the median duration of follow-up available was 112 days.

MORE INFORMATION:

Manufacturer: Sinopharm Group
Number of Shots: 2 shots, 3 to 4 weeks apart
Type of Vaccine: Inactivated

Vaccine effectiveness against COVID-19 of any severity was 78 percent 14 or more days after dose 2. The effectiveness of vaccines against severe disease is 93%. Adults aged less than 60 years had a 79 percent efficacy rate, whereas those aged 60 and over had a 68 percent efficacy rate.

Vaccine efficacy against all variant-related COVID-19 illness was 71%, with 90% efficacy against Kappa and 65% efficacy against Delta. In light of these findings, WHO recommends using the BBV152 vaccine in accordance with the WHO Prioritization Roadmap, even if the nation contains currently recognized Variants of Concern (VOC). If new VOCs emerge that impact vaccination performance, these recommendations will be updated accordingly. There is currently no information available for Omicron.

MORE INFORMATION:
Manufacturer: Bharat Biotech International Limited (BBIL)
Number of Shots: 2 shots, less than 4 weeks apart
Type of Vaccine: Inactivated